Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,903 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Afatinib in Untreated Stage IIIB/IV Lung Adenocarcinoma with Major Uncommon Epidermal Growth Factor Receptor (EGFR) Mutations (G719X/L861Q/S768I): A Multicenter Observational Study in Taiwan.
Hsu PC, Lee SH, Chiu LC, Lee CS, Wu CE, Kuo SC, Ju JS, Huang AC, Li SH, Ko HW, Yang CT, Wang CC. Hsu PC, et al. Among authors: li sh. Target Oncol. 2023 Mar;18(2):195-207. doi: 10.1007/s11523-023-00946-w. Epub 2023 Feb 20. Target Oncol. 2023. PMID: 36805452 Free PMC article.
Comparison of afatinib and erlotinib combined with bevacizumab in untreated stage IIIB/IV epidermal growth factor receptor-mutated lung adenocarcinoma patients: a multicenter clinical analysis study.
Lee SH, Lin YC, Chiu LC, Ju JS, Tung PH, Huang AC, Li SH, Fang YF, Chen CH, Kuo SC, Wang CC, Yang CT, Hsu PC. Lee SH, et al. Among authors: li sh. Ther Adv Med Oncol. 2022 Jul 23;14:17588359221113278. doi: 10.1177/17588359221113278. eCollection 2022. Ther Adv Med Oncol. 2022. PMID: 35898964 Free PMC article.
Continuous epidermal growth factor receptor-tyrosine kinase inhibitor administration in primary lung adenocarcinoma patients harboring favorable mutations with controlled target lung tumors dose not hinder survival benefit despite small new lesions.
Hsu PC, Chiu LC, Li SH, Chen CH, Wang CL, Kao KC, Chang JW, Wang CW, Yu CT, Chung FT, Yang CT, Liu CY. Hsu PC, et al. Among authors: li sh. Biomed J. 2016 Apr;39(2):121-9. doi: 10.1016/j.bj.2015.07.002. Epub 2016 Jun 9. Biomed J. 2016. PMID: 27372167 Free PMC article.
The efficacy of 40 mg versus dose de-escalation to less than 40 mg of afatinib (Giotrif) as the first-line therapy for patients with primary lung adenocarcinoma harboring favorable epidermal growth factor mutations.
Liu CY, Wang CL, Li SH, Hsu PC, Chen CH, Lin TY, Kuo CH, Fang YF, Ko HW, Yu CT, Yang TY, Yang CT. Liu CY, et al. Among authors: li sh. Oncotarget. 2017 Jun 27;8(57):97602-97612. doi: 10.18632/oncotarget.18746. eCollection 2017 Nov 14. Oncotarget. 2017. PMID: 29228636 Free PMC article.
Oral vinorelbine plus cisplatin with concomitant radiotherapy as induction therapy for stage III non-small cell lung cancer: Results of a single-arm prospective cohort study.
Hsu PC, Chang JW, Wang CC, Wu CT, Lin YC, Wang CL, Lin TY, Li SH, Wu YC, Kuo SC, Yang CT, Liu CY, Chen CH. Hsu PC, et al. Among authors: li sh. Thorac Cancer. 2019 Aug;10(8):1683-1691. doi: 10.1111/1759-7714.13125. Epub 2019 Jul 5. Thorac Cancer. 2019. PMID: 31276309 Free PMC article.
Zinc deficiency associated with cutaneous toxicities induced by epidermal growth factor receptor tyrosine kinase inhibitor therapy in patients with lung adenocarcinoma.
Lu CW, Pang JS, Ko YS, Chang CJ, Wang CW, Chen WT, Chen CB, Hui RC, Hung SI, Lu LY, Lu KL, Wang CL, Wu CE, Hsu PC, Fang YF, Li SH, Ko HW, Tseng LC, Shih FY, Chen MJ, Chung WH. Lu CW, et al. Among authors: li sh. J Eur Acad Dermatol Venereol. 2023 Feb;37(2):328-339. doi: 10.1111/jdv.18703. Epub 2022 Nov 16. J Eur Acad Dermatol Venereol. 2023. PMID: 36366861
1,903 results